Bio-Hermes-002

iLoF, the leading innovator in AI-powered photonics platforms for personalised medicine, announces today a strategic investment from Hamamatsu, the world expert in the development and manufacturing of photonics devices and systems for medical optics and biophotonics, to further its mission of transforming healthcare and driving innovation in medicine. LONDON, Oct. 22, 2024 /PRNewswire/ — iLoF, the leading company […]

The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study   Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]

What we do Dementia and Neurodegeneration was identified as one of the key healthcare missions in the 2021 Life Sciences Vision. Dementia is the leading cause of death in England and one in two people will be directly affected by it – either they will care for someone with the condition, develop it themselves, or both. […]

NEWS PROVIDED BYiLoF , Jul 31, 2024, 09:28 ET The international clinical study, Bio-Hermes-002, establishes an ambitious transnational collaboration aimed at achieving a breakthrough in Alzheimer’s diagnosis and treatment. LONDON and ROCHESTER, N.Y., July 31, 2024 /PRNewswire/ — iLoF, a global deep tech digital health company, today announced it has secured a £1.2M (~$1.5M) clinical research contract from Innovate UK, […]

10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]